Endoscopic Injection Therapy

Overview

Journal Investig Clin Urol

Specialty Urology

Date 2017 Jun 15

PMID 28612059

Citations 9

Authors

Sang Woon Kim

Yong Seung Lee

Sang Won Han

Affiliations

Soon will be listed here.

Abstract

Since the U.S. Food and Drug Administration approved dextranomer/hyaluronic acid copolymer (Deflux) for the treatment of vesicoureteral reflux, endoscopic injection therapy using Deflux has become a popular alternative to open surgery and continuous antibiotic prophylaxis. Endoscopic correction with Deflux is minimally invasive, well tolerated, and provides cure rates approaching those of open surgery (i.e., approximately 80% in several studies). However, in recent years a less stringent approach to evaluating urinary tract infections (UTIs) and concerns about long-term efficacy and complications associated with endoscopic injection have limited the use of this therapy. In addition, there is little evidence supporting the efficacy of endoscopic injection therapy in preventing UTIs and vesicoureteral reflux-related renal scarring. In this report, we reviewed the current literature regarding endoscopic injection therapy and provided an updated overview of this topic.

Citing Articles

Efficacy of Three Different Injection Techniques for the Endoscopic Treatment of Vesicoureteral Reflux (VUR) in Children: A Review of 10 Years of Experience.

Lanfranchi G, Paraboschi I, Pierucci U, Mantica G, Costanzo S, Marinoni F Res Rep Urol. 2024; 16:151-159.

PMID: 38975061 PMC: 11227862. DOI: 10.2147/RRU.S467018.

Therapeutic Management of Children with Vesicoureteral Reflux.

Chirico V, Tripodi F, Lacquaniti A, Monardo P, Conti G, Ascenti G J Clin Med. 2024; 13(1).

PMID: 38202251 PMC: 10779648. DOI: 10.3390/jcm13010244.

Efficacy and safety of Hyadex for treatment of vesicoureteral reflux: a multicenter experience.

Oguz F, Yildiz T, Gecit I, Gungor H, Ciftci H, Aksoy Y J Int Med Res. 2023; 51(8):3000605231195165.

PMID: 37646623 PMC: 10469260. DOI: 10.1177/03000605231195165.

Endoscopic injection of bulking agents in pediatric vesicoureteral reflux: a narrative review of the literature.

Escolino M, Kalfa N, Castagnetti M, Caione P, Esposito G, Florio L Pediatr Surg Int. 2023; 39(1):133.

PMID: 36806763 PMC: 9938816. DOI: 10.1007/s00383-023-05426-w.

Magnetic Agarose Microspheres/Hyaluronic Acid Hydrogel as a Trackable Bulking Agent for Vesicoureteral Reflux Treatment.

Chen H, Wu P, Xu H, Wang C Front Bioeng Biotechnol. 2021; 9:746609.

PMID: 34692663 PMC: 8529187. DOI: 10.3389/fbioe.2021.746609.

References

Lendvay T, Sorensen M, Cowan C, Joyner B, Mitchell M, Grady R . The evolution of vesicoureteral reflux management in the era of dextranomer/hyaluronic acid copolymer: a pediatric health information system database study. J Urol. 2006; 176(4 Pt 2):1864-7. DOI: 10.1016/j.juro.2006.04.088. View

Chertin B, Natsheh A, Fridmans A, Shenfeld O, Farkas A . Renal scarring and urinary tract infection after successful endoscopic correction of vesicoureteral reflux. J Urol. 2009; 182(4 Suppl):1703-6. DOI: 10.1016/j.juro.2009.03.011. View

Lackgren G, Skoldenberg E, Stenberg A . Endoscopic treatment with stabilized nonanimal hyaluronic acid/dextranomer gel is effective in vesicoureteral reflux associated with bladder dysfunction. J Urol. 2007; 177(3):1124-8. DOI: 10.1016/j.juro.2006.10.094. View

Kirsch A, Arlen A, Lackgren G . Current trends in dextranomer hyaluronic acid copolymer (Deflux) injection technique for endoscopic treatment of vesicoureteral reflux. Urology. 2014; 84(2):462-8. DOI: 10.1016/j.urology.2014.04.032. View

Chertin B, Colhoun E, Velayudham M, Puri P . Endoscopic treatment of vesicoureteral reflux: 11 to 17 years of followup. J Urol. 2002; 167(3):1443-5; discussion 1445-6. DOI: 10.1016/s0022-5347(05)65340-2. View

Yucel S, Tarcan T, Simsek F . Durability of a single successful endoscopic polytetrafluoroethylene injection for primary vesicoureteral reflux: 14-year followup results. J Urol. 2007; 178(1):265-8. DOI: 10.1016/j.juro.2007.03.060. View

Chertin B, Kocherov S . Long-term results of endoscopic treatment of vesicoureteric reflux with different tissue-augmenting substances. J Pediatr Urol. 2009; 6(3):251-6. DOI: 10.1016/j.jpurol.2009.10.011. View

Brandstrom P, Neveus T, Sixt R, Stokland E, Jodal U, Hansson S . The Swedish reflux trial in children: IV. Renal damage. J Urol. 2010; 184(1):292-7. DOI: 10.1016/j.juro.2010.01.060. View

Dave S, Lorenzo A, Khoury A, Braga L, Skeldon S, Suoub M . Learning from the learning curve: factors associated with successful endoscopic correction of vesicoureteral reflux using dextranomer/hyaluronic acid copolymer. J Urol. 2008; 180(4 Suppl):1594-9. DOI: 10.1016/j.juro.2008.03.084. View

10.

Karakus S, User I, Demircioglu Kilic B, Akcaer V, Ceylan H, Ozokutan B . The comparison of dextranomer/hyaluronic acid and polyacrylate-polyalcohol copolymers in endoscopic treatment of vesicoureteral reflux. J Pediatr Surg. 2016; 51(9):1496-500. DOI: 10.1016/j.jpedsurg.2016.02.092. View

11.

Yucel S, Gupta A, Snodgrass W . Multivariate analysis of factors predicting success with dextranomer/hyaluronic acid injection for vesicoureteral reflux. J Urol. 2007; 177(4):1505-9. DOI: 10.1016/j.juro.2006.11.077. View

12.

Peters C, Skoog S, Arant Jr B, Copp H, Elder J, Hudson R . Summary of the AUA Guideline on Management of Primary Vesicoureteral Reflux in Children. J Urol. 2010; 184(3):1134-44. DOI: 10.1016/j.juro.2010.05.065. View

13.

Aaronson I, Rames R, Greene W, Walsh L, Hasal U, Garen P . Endoscopic treatment of reflux: migration of Teflon to the lungs and brain. Eur Urol. 1993; 23(3):394-9. DOI: 10.1159/000474637. View

14.

Molitierno Jr J, Scherz H, Kirsch A . Endoscopic injection of dextranomer hyaluronic acid copolymer for the treatment of vesicoureteral reflux in duplex ureters. J Pediatr Urol. 2008; 4(5):372-6. DOI: 10.1016/j.jpurol.2008.01.216. View

15.

Kalisvaart J, Scherz H, Cuda S, Kaye J, Kirsch A . Intermediate to long-term follow-up indicates low risk of recurrence after Double HIT endoscopic treatment for primary vesico-ureteral reflux. J Pediatr Urol. 2011; 8(4):359-65. DOI: 10.1016/j.jpurol.2011.07.006. View

16.

Rubenwolf P, Ebert A, Ruemmele P, Rosch W . Delayed-onset ureteral obstruction after endoscopic dextranomer/hyaluronic acid copolymer (Deflux) injection for treatment of vesicoureteral reflux in children: a case series. Urology. 2013; 81(3):659-62. DOI: 10.1016/j.urology.2012.11.044. View

17.

Moorthy I, Easty M, McHugh K, Ridout D, Biassoni L, Gordon I . The presence of vesicoureteric reflux does not identify a population at risk for renal scarring following a first urinary tract infection. Arch Dis Child. 2005; 90(7):733-6. PMC: 1720473. DOI: 10.1136/adc.2004.057604. View

18.

Vandenbossche M, Delhove O, Dumortier P, Deneft F, Schulman C . Endoscopic treatment of reflux: experimental study and review of Teflon and collagen. Eur Urol. 1993; 23(3):386-93. DOI: 10.1159/000474636. View

19.

Lackgren G, Kirsch A . Surgery Illustrated - Surgical Atlas Endoscopic treatment of vesicoureteral reflux. BJU Int. 2010; 105(9):1332-47. DOI: 10.1111/j.1464-410X.2010.09325.x. View

20.

Nelson C, Copp H, Lai J, Saigal C . Is availability of endoscopy changing initial management of vesicoureteral reflux?. J Urol. 2009; 182(3):1152-7. PMC: 2726896. DOI: 10.1016/j.juro.2009.05.049. View